Firsocostat (formerly also known as ND-630; GS-0976; NDI-010976; ND630) is a novel and potent inhibitor of ACC (acetyl-CoA carboxylase) with IC50 values of 2.1 and 6.1 nM for human ACC1 and ACC2, respectively.

TOFA (5‑tetradecyloxy‑2‑furoic acid), also known as RMI14514 and MDL14514, is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA).

PF-05175157 (PF05175157) is a novel, potent and selective broad spectrum inhibitor of acetyl-CoA carboxylase (ACC) with anti-diabetic and anticancer activity.

ND-646 is-an allosteric inhibitor of the ACC enzymes ACC1 and ACC2 that prevents ACC subunit dimerization-to suppress fatty acid synthesis in vitro and in vivo.

CP-640186 is a novel, potent and and cell-permeable inhibitor of mammalian ACCs (isozyme-nonselective acetyl-CoA carboxylase) with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively; It hash improved metabolic stability in comparison to CP-610431, an analog of CP-640186.

ND-630 S enantiomer, the S enantiomer of ND-630 (also known as GS-0976; NDI-010976; firsocostat), is a potent inhibitor of ACC (acetyl-CoA carboxylase).

MK-4074 is a novel, potent and liver-specific inhibitor of acetyl-CoA carboxylase ACC1 and ACC2 which are enzymes that produce malonyl-CoA for fatty acid synthesis, with IC50 values of 3 nM.

CP-640186 HCl is a novel and potent inhibitor of mammalian ACCs (isozyme-nonselective acetyl-CoA carboxylase) with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively; It hash improved metabolic stability in comparison to CP-610431, an analog of CP-640186.

CMS-121 (CMS121) is a novel and potent fisetin-based quinolone derivative acting as an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor with anti-aging, neuroprotective, anti-inflammatory, antioxidative, and renoprotective activities.